Imago BioSciences

San Carlos, CA · Founded 2012 · Biotech · Acquired

LSD1 inhibitor small-molecule therapeutic for myeloproliferative neoplasms

Claim this profile

Follows are private to you and power your alerts

Updated · imagobio.com

Sector
Biotech
Headquarters
San Carlos, CA
Founded
2012
Latest Form D
$80M, Nov 2020
Total capital
$106M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$106M
3 Form D · last Nov 2020
71 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
11
29 pending · first 2017
Rank in peer group#156 of 1449

Capital timeline

2014201520162017201820192020FEDERAL ↑EQUITY ↓Cumulative $106M1st Form D$8.8M2nd Form D$17M3rd Form D$80M
2014201620182020FEDERAL ↑EQUITY ↓Cumulative $106M1st Form D$8.8M2nd Form D$17M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$80M
  • Private capital raisedForm D · SEC · 2nd filing$17M
  • Private capital raisedForm D · SEC · 1st filing$8.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#156 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Hugh Y. Rienhoff, Jr.ResearcherExecutive Officer, DirectorLinked by 1 patent
  • Alan G. SachsDirectorNamed in SEC Form D filings
  • Dennis` J. HennerDirectorNamed in SEC Form D filings
  • Dennis G. HennerDirectorNamed in SEC Form D filings
  • Dina Chaya MoghrabiDirectorNamed in SEC Form D filings
  • Harish Chaya SoundararajanDirectorNamed in SEC Form D filings
Show all 10 people
  • Hugh Y. RienhoffExecutive Officer, DirectorNamed in SEC Form D filings
  • Laura G. EichornExecutive OfficerNamed in SEC Form D filings
  • Patrick G. HeronDirectorNamed in SEC Form D filings
  • Robert Chaya BalteraDirectorNamed in SEC Form D filings

What it has protected

USPTO · 11 granted of 40
  • PendingKDM1A Inhibitors For The Treatment Of DiseaseUSPTOApplication 19137840
  • PendingMethods For Treatment Of Bone Marrow Failure And Related ConditionsUSPTOApplication 19137870
  • PendingMethods For The Enhancement Of Therapeutic Effect Of Car-t CellsUSPTOApplication 18867042
Show all 40 patent records
  • KDM1A Inhibitors For The Treatment Of DiseaseMar 26, 2026 · Application 19137840Pending
  • Methods For Treatment Of Bone Marrow Failure And Related ConditionsMar 26, 2026 · Application 19137870Pending
  • Methods For The Enhancement Of Therapeutic Effect Of Car-t CellsSep 18, 2025 · Application 18867042Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseJan 30, 2025 · Application 18702005Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseMar 19, 2024 · US 11,932,629Granted
  • KDM1A Inhibitors For The Treatment Of DiseaseOct 3, 2023 · US 11,773,068Granted
  • Pharmaceutical Formulations For Treating Diseases Mediated By KDM1ASep 21, 2023 · Application 18188578Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseMay 23, 2023 · US 11,655,226Granted
  • Methods And Processes For The Preparation Of KDM1A InhibitorsApr 6, 2023 · Application 17807061Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseFeb 14, 2023 · US 11,578,059Granted
  • Lysine-specific Histone Demethylase Inhibitors For The Treatment Of Myeloproliferative NeoplasmsJan 5, 2023 · Application 17805130Pending
  • Methods And Processes For The Preparation Of KDM1A InhibitorsJul 19, 2022 · US 11,390,590Granted
  • Compositions And Methods For Producing Stereoisomerically Pure AminocyclopropanesJan 27, 2022 · Application 16326498Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseJan 25, 2022 · US 11,230,534Granted
  • Lysine-specific Histone Demethylase Inhibitors For The Treatment Of Myeloproliferative NeoplasmsDec 16, 2021 · Application 17350321Pending
  • Lysine-specific Histone Demethylase As A Novel Therapeutic Target In Myeloproliferative NeoplasmsJul 1, 2021 · Application 17144810Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseJan 5, 2021 · US 10,882,835Granted
  • KDM1A Inhibitors For The Treatment Of DiseaseDec 31, 2019 · US 10,519,118Granted
  • KDM1A Inhibitors For The Treatment Of DiseaseAug 6, 2019 · US 10,370,346Granted
  • Lysine-specific Histone Demethylase As A Novel Therapeutic Target In Myeloproliferative NeoplasmsMar 7, 2019 · Application 15773911Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseMay 29, 2018 · US 9,981,922Granted
  • KDM1A Inhibitors For The Treatment Of DiseaseOct 17, 2017 · US 9,790,195Granted
  • Lysine-Specific Histone Demethylase, LSD1, (KDM1A) As a Novel Therapeutic Target in Myeloproliferative NeoplasmsApplication 62251674Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication 62115474Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication PCTUS2014049906Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication 61954276Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication PCTUS2014023659Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication 61862759Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication 61776000Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication PCTUS2023084162Pending
  • Methods For Treatment Of Bone Marrow Failure And Related ConditionsApplication PCTUS2023084159Pending
  • Methods For The Enhancement Of Therapeutic Effect Of Car-t CellsApplication PCTUS2023067222Pending
  • Methods For Treatment Of Bone Marrow Failure And Related ConditionsApplication 63477020Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication 63476990Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication PCTUS2022078187Pending
  • Methods For The Enhancement Of Therapeutic Effect Of Car-t CellsApplication 63365075Pending
  • KDM1A Inhibitors For The Treatment Of DiseaseApplication 63256850Pending
  • Pharmaceutical Formulations For Treating Diseases Mediated By KDM1AApplication PCTUS2021053141Pending
  • Lysine-specific Histone Demethylase Inhibitors For The Treatment Of Myeloproliferative NeoplasmsApplication PCTUS2020063773Pending
  • Lysine-specific Histone Demethylase Inhibitors For The Treatment Of Myeloproliferative NeoplasmsApplication 63121461Pending
  • Third Arc Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • 4D Molecular Therapeutics IncSimilar federal contract value in Biotech · null in contracts
  • Pyxis OncologySimilar federal contract value in Biotech · null in contracts
  • Dianthus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • AUXAGEN, INC.Similar federal contract value in Biotech · null in contracts
  • ANOVAC, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .